Anti-Kelch-like protein 11 antibody encephalitis: a case report and literature review.
KLHL11 antibody
autoimmune encephalitis
case report
cerebellar syndrome
paraneoplastic neurological syndrome
Journal
Frontiers in neurology
ISSN: 1664-2295
Titre abrégé: Front Neurol
Pays: Switzerland
ID NLM: 101546899
Informations de publication
Date de publication:
2023
2023
Historique:
received:
05
08
2023
accepted:
02
10
2023
medline:
13
11
2023
pubmed:
13
11
2023
entrez:
13
11
2023
Statut:
epublish
Résumé
Anti-Kelch-like protein 11 (KLHL11) antibody encephalitis is a rare clinical condition characterized by autoimmune-mediated encephalomyelitis associated with the presence of KLHL11 antibodies. Diagnosis requires the detection of serum and cerebrospinal fluid anti-KLHL11 antibodies, while immunotherapy serves as the principal treatment approach. This paper presents a case report highlighting the emergence of anti-KLHL11 antibody encephalitis. A 66-year-old male patient presented with seizures, impaired cognitive function, disturbance of consciousness, apathy, hypologia, dysphoria, and ataxia. Serum and cerebrospinal fluid (CSF) were identified as positive for anti-KLHL11 antibodies, leading to a diagnosis of autoimmune encephalitis associated with KLHL11 antibodies. After treatment with glucocorticoid, the patient did not experience further convulsions and recovered consciousness, with improved cognitive function. Tumor screening suggested the presence of an underlying malignancy. The clinical manifestations of anti-KLHL11 antibody encephalitis vary widely, and timely identification and treatment can improve prognosis.
Identifiants
pubmed: 37954647
doi: 10.3389/fneur.2023.1273051
pmc: PMC10637383
doi:
Types de publication
Case Reports
Langues
eng
Pagination
1273051Informations de copyright
Copyright © 2023 Song, Hu and Zhang.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Mov Disord Clin Pract. 2020 Dec 30;8(2):215-216
pubmed: 33553490
N Engl J Med. 2019 Jul 4;381(1):89-91
pubmed: 31269373
Eur J Neurol. 2021 Dec;28(12):4261-4266
pubmed: 34561925
JAMA Neurol. 2021 Aug 1;78(8):1016-1017
pubmed: 34047764
Neurology. 2020 Jul 21;95(3):134-135
pubmed: 32561677
J Neuroophthalmol. 2021 Jun 1;41(2):261-265
pubmed: 33630775
Mov Disord Clin Pract. 2021 Sep 03;8(Suppl 1):S42-S44
pubmed: 34514048
Neurology. 2022 Mar 29;98(13):543-549
pubmed: 35121670
Ann Neurol. 2021 May;89(5):1001-1010
pubmed: 33583072
Brain Commun. 2021 Aug 26;3(3):fcab185
pubmed: 34557666
J Neurol Neurosurg Psychiatry. 2021 Nov;92(11):1181-1185
pubmed: 34285066
Neurol Neuroimmunol Neuroinflamm. 2020 Jan 17;7(3):
pubmed: 31953318
J Neuroimmunol. 2021 Jun 15;355:577570
pubmed: 33862421
JAMA Neurol. 2020 Nov 1;77(11):1420-1429
pubmed: 32744608
Eur J Neurol. 2023 Jun;30(6):1801-1814
pubmed: 36815561
N Engl J Med. 2019 Jul 4;381(1):47-54
pubmed: 31269365
Acta Neurol Belg. 2022 Feb;122(1):257-258
pubmed: 34655037
Mayo Clin Proc. 2022 Jan;97(1):122-123
pubmed: 34996544
Neurology. 2021 May 25;96(21):e2668-e2669
pubmed: 33589533